Health Care·Biotechnology·$4.4B
Legend Biotech Corp is a biotechnology company focused on developing innovative cell therapies for cancer treatment. Operating in the health care sector, it plays a crucial role in advancing medical solutions that could significantly improve patient outcomes.
EPS
Earnings per share is a key indicator of the company's profitability and financial health.
Revenue
While revenue estimates are not available, any reported figures will provide insight into the company's market performance.
Wall Street expectations, options signals, track record, and call prep available with Pro.
EPS Beat Streak
1Q
EPS Beat Rate
67%
Avg EPS Surprise
+12.73%
Avg Stock Reaction
+3.44%
In Q1 2024, Legend Biotech reported an EPS of -$0.16, which was better than the expected -$0.29, resulting in a positive surprise. However, the stock experienced a slight decline of 0.62% the following day.
Management Promises & Guidance
Overall expectations for Legend Biotech's upcoming earnings are uncertain due to the lack of analyst estimates and management guidance. Investors will be closely watching for any signs of revenue growth or improvements in EPS.
Bull Case
If Legend Biotech can report better-than-expected EPS and provide positive insights into its pipeline or future revenue, it could lead to a significant rally in the stock price.
Bear Case
Conversely, if the company reports a larger-than-expected loss or fails to provide clarity on its future prospects, it may lead to a sell-off.
EPS
N/AEarnings per share is a key indicator of the company's profitability and financial health.
Revenue
N/AWhile revenue estimates are not available, any reported figures will provide insight into the company's market performance.
The print will turn on these two things.
Q1
What will the EPS be for Q1-2026?
The EPS figure will be crucial in assessing the company's financial performance and investor sentiment.
Q2
How is the company progressing with its pipeline of therapies?
Updates on the pipeline could significantly influence investor confidence and expectations for future revenue.
Why consensus could be wrong
The Street may be underestimating the potential for Legend Biotech's pipeline to yield significant breakthroughs, which could lead to better-than-expected results.
Supporting Evidence
The company has a history of beating EPS estimates, with a 67% success rate over the last six quarters.
Recent advancements in biotechnology suggest a favorable environment for innovative therapies, which could benefit Legend Biotech.
The lack of analyst estimates may mean that the market is not fully pricing in the potential upside from new product developments.
Key Risk
If the company announces a significant partnership or breakthrough in its therapies, it could dramatically shift market expectations.
Pre-commit to what would confirm each case.
The upcoming earnings report is critical as it will provide insights into the company's financial health and future growth potential.
Bull Confirmed If
Reporting an EPS better than -$0.16 would signal strong operational performance.
Bear Confirmed If
An EPS worse than -$0.16 could confirm ongoing challenges in profitability.
Implied Move
±N/A
There is no options market data available to gauge investor sentiment ahead of the earnings report.
Likely market behavior by outcome — not investment advice.
Beat & Raise
If Legend Biotech beats expectations, history suggests the stock could rise around 1.71% on the following day, confirming a positive outlook.
In-Line / Cautious
If results are in line with expectations, the stock may see muted movement as investors await further guidance.
Miss
Should the company miss expectations, history suggests a potential decline of around 6.91%, reflecting investor disappointment.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
WORKDAY INC A
Nov 29, 2022